Newswise — Lawrenceville, NJ, USA—September 18, 2018—Value in Health, the official journal of ISPOR (the professional society for health economics and outcomes research), announced today the publication of a series of articles that tackle the challenges associated with assessing the value of next-generation sequencing technologies in clinical care. The special themed section appears in the September 2018 issue of Value in Health. The section guest editor is Kathryn A. Phillips, PhD, University of California at San Francisco, San Francisco, CA, USA.
As next-generation sequencing-based tests are increasingly being used in the clinic, health technology assessment organizations, health insurance companies, and governments must assess their clinical and economic value. In recent years, consensus has been emerging that conventional frameworks used by payers to assess the value of new drugs are not well suited for evaluating the value of genomic testing. The 5 articles in the themed section are introduced in an editorial in which D. Phillips notes that each paper adds to the literature by going beyond just identifying challenges to identifying potential solutions, using both systematic reviews and case studies. The papers incorporate a wide range of perspectives and topics, but all focus on the overarching issue of how to appropriately consider and assess the value of next-generation sequencing:
In her introductory editorial, Dr Phillips notes that the themed section focuses specifically on next-generation sequencing, which is the fastest growing type of precision medicine technology. “As genetic testing evolves from the use of single-gene tests toward the use of more complex tests that measure multiple genes using high-speed DNA sequencing technologies—that is, next-generation sequencing—it is critical that we assess the value of such testing,” said Dr Phillips. “But there are many methodological challenges to doing so. All of the papers in this special section ‘push the envelope’ by delving into solutions so as to move the agenda forward. We trust that our findings will be useful not only to health economist researchers but also to other stakeholders, including clinical researchers, payers and industry.”
###
ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg
ABOUT VALUE IN HEALTH
Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2017 impact factor score is 5.494. Value in Health is ranked 3rd among 94 journals in healthcare sciences and services, 3rd among 79 journals in health policy and services, and 6th among 353 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.
Web: www.ispor.org/valueinhealth_index.asp | Twitter: www.twitter.com/ISPORJournals (@ISPORjournals)
RSS